| 1 |
34953979 | Paclitaxel derivative-based liposomal nanoplatform for potentiated chemo-immunotherapy. | 2022 Jan |
2 |
| 2 |
35059287 | A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab. | 2022 |
1 |
| 3 |
35440807 | Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21. | 2022 Apr 19 |
2 |
| 4 |
35619841 | Prolonged Response of Metastatic Programmed Death-Ligand 1 (PD-L1) Negative Basaloid Squamous Cell Carcinoma of the Lung to Maintenance Immunotherapy. | 2022 Apr |
1 |
| 5 |
33030848 | Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer. | 2021 Apr 1 |
2 |
| 6 |
33030957 | Loss of tumor intrinsic PD-L1 confers resistance to drug-induced apoptosis in human colon cancer. | 2021 Jan |
1 |
| 7 |
33475294 | Immunotherapy in Triple-Negative Breast Cancer. | 2021 Jan-Feb 01 |
1 |
| 8 |
33866918 | The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death. | 2021 Dec |
1 |
| 9 |
34161810 | Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles. | 2021 Aug 10 |
1 |
| 10 |
34219000 | Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. | 2021 Aug |
1 |
| 11 |
34359638 | Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. | 2021 Jul 25 |
1 |
| 12 |
34653365 | Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. | 2021 Dec 13 |
1 |
| 13 |
34687372 | The effects of chemotherapeutic drugs on PD-L1 gene expression in breast cancer cell lines. | 2021 Oct 23 |
1 |
| 14 |
34717654 | Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma. | 2021 Oct 30 |
1 |
| 15 |
34742008 | Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer. | 2021 Dec |
1 |
| 16 |
34761351 | The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer. | 2021 Nov 10 |
1 |
| 17 |
34778188 | Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis. | 2021 |
2 |
| 18 |
34855343 | Cascade-Responsive Hierarchical Nanosystems for Multisite Specific Drug Exposure and Boosted Chemoimmunotherapy. | 2021 Dec 15 |
1 |
| 19 |
31966052 | PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer. | 2020 Feb |
2 |
| 20 |
32001481 | FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1. | 2020 May 15 |
1 |
| 21 |
32129476 | The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. | 2020 Apr |
1 |
| 22 |
32166458 | PD-L1 monoclonal antibody-decorated nanoliposomes loaded with Paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers. | 2020 Mar 12 |
3 |
| 23 |
32408327 | [A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation]. | 2020 May |
1 |
| 24 |
32426048 | Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer. | 2020 |
4 |
| 25 |
32440550 | Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy. | 2020 May |
1 |
| 26 |
32450725 | Atezolizumab in the treatment of metastatic triple-negative breast cancer. | 2020 Sep |
1 |
| 27 |
32574155 | A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer. | 2020 Jun 23 |
3 |
| 28 |
32591993 | HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line. | 2020 Oct |
1 |
| 29 |
32609449 | Lichenoid inflammation of DSAP lesions following treatment with durvalumab, olaparib and paclitaxel: A potential diagnostic pitfall mimicking lichenoid drug eruptions associated with PDL-1 inhibitors. | 2020 Mar 15 |
1 |
| 30 |
32669274 | Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter. | 2020 Jul 15 |
1 |
| 31 |
32988260 | Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer. | 2020 Dec |
1 |
| 32 |
33014143 | Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. | 2020 |
1 |
| 33 |
33043814 | Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer. | 2020 Oct 2 |
1 |
| 34 |
30770442 | Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. | 2019 Mar 5 |
2 |
| 35 |
31772851 | Nivolumab plus Carboplatin and Paclitaxel as the First-line Therapy for Advanced Squamous Cell Carcinoma of the Lung with Strong Programmed Death-ligand 1 Expression: A Case Report. | 2019 Oct 10 |
1 |
| 36 |
31839159 | Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). | 2019 Nov |
1 |
| 37 |
31842957 | Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. | 2019 Dec 16 |
1 |
| 38 |
32042863 | Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. | 2019 Sep |
1 |
| 39 |
32309609 | Immunotherapy for Breast Cancer: First FDA Approved Regimen. | 2019 Mar 31 |
2 |
| 40 |
29438316 | Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice. | 2018 Feb 13 |
2 |
| 41 |
29675791 | Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. | 2018 Jul |
1 |
| 42 |
30345906 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. | 2018 Nov 29 |
1 |
| 43 |
28112370 | The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. | 2017 Mar |
2 |
| 44 |
28415820 | Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. | 2017 May 2 |
2 |
| 45 |
31271140 | Efficient Suppression of Liver Metastasis Cancers by Paclitaxel Loaded Nanoparticles in PDLLA-PEG-PDLLA Thermosensitive Hydrogel Composites. | 2017 Nov 1 |
1 |
| 46 |
27181838 | PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. | 2016 May 16 |
2 |
| 47 |
27930644 | Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. | 2016 Nov |
1 |
| 48 |
22005063 | Paclitaxel induced B7-H1 expression in cancer cells via the MAPK pathway. | 2011 Oct |
4 |
| 49 |
17920123 | Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. | 2008 Mar |
1 |